Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 18 of 18 publications.

Maurer M, Houghton K, Costa C, Dabove F, Ensina LF, Gimenez-Arnau A, Guillet G, Konstantinou GN, Labrador-Horrillo M, Lapeere H, Meshkova R, Pastorello E, Velasquez-Lopera M, Tamayo Quijano LM, Vestergaard C, Chapman-Rothe N. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organ J. 2018 Nov 16;11(32). doi: 10.1186/s40413-018-0216-1

Augustin M, Krieger T, Mcbride D, Graham C, Melzer N, Kneidl J, Gutknecht M, Neidhardt K. Kosten-effektivität von secukinumab in der induktionstherapie der psoriasis in Deutschland. Poster presented at the 49th German Society of Dermatology (DDG) Conference; April 26, 2017. Berlin, Germany. [abstract] J Dtsch Dermatol Ges. 2017 Apr; 15(S1):130-1. doi: 10.1111/ddg.13213

Singh M, Rebordosa C, Bernholz J, Sharma N. Epidemiology and genetics of cystic fibrosis in Asia: in preparation for the next-generation treatments. Respirology. 2015 Nov 6;20(8):1172-81. doi: 10.1111/resp.12656

Vickers AD, Mody R, Bergman A, Ling CS, Ainsworth C, Medjedovic J, Smyth M. Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): a systematic review and network meta-analysis. Poster presented at the 2015 Digestive Disease Week; May 2015. Washington, DC. [abstract] Gastroenterology. 2015 Apr 16; 148(4, Suppl 1):S272. Previously presented at the 10th Congress of the European Crohn's and Colitis Organization.

Odom DM, Mladsi DM, Saag K, Ronquest NA, Wang J. Estimating the relationship between diclofenac drug dosage and risk of gastrointestinal toxicity: meta-regression based on a systematic literature review. Poster presented at the 2013 Digestive Disease Week; May 2013. Orlando, FL. [abstract] Gastroenterology. 2013 May; 144(5 Suppl 1):S-673. doi: 10.1016/S0016-5085(13)62496-8

Phipps AI, Newcomb PA, Garcia-Albeniz X, Hutter CM, White E, Fuchs CS, Hazra A, Ogino S, Nan H, Ma J, Campbell PT, Figueiredo JC, Peters U, Chan AT. Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer. Gastroenterology. 2012 Jul;143(1):51-4. doi: 10.1053/j.gastro.2012.04.052

Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology. 2011 Nov;16(8):1235-40. doi: 10.1111/j.1440-1843.2011.02030.x

Carroll IM, Ringel-Kulka T, keku TP, Chang Y-H, Packey CD, Neil SK, Williamson D, Sartor RB, Ringel Y. Molecular characterization of the fecal and colonic mucosal-associated microbiota in diarrhea-predominant irritable bowel syndrome patients. Poster presented at the Digestive Disease Week; May 7, 2011. Chicago, IL. [abstract] Gastroenterology. 2011 May; 140(5, Suppl 1):S373. doi: 10.1016/S0016-5085(11)61523-0

Chung RT, Bisceglie A, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Hamzeh FM. Association of host pharmacodynamic effects and virologic response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis c. Poster presented at the 2010 Digestive Disease Week; May 1, 2010. New Orleans, LA. [abstract] Gastroenterology. 2010 May; 138(5_suppl_1):S-841.

Spiegel B, Camilleri M, Bolus R, Andresen V, Chey WD, Fehnel S, Mangel A, Talley NJ, Whitehead WE. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome foundation report. Gastroenterology. 2009 Dec 1;137(6):1944-53.

Johnson FR, Ozdemir F, Mansfield CA, Hass S, Miller DP, Siegel CA, Sands BE. Crohn's disease patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007 Sep;133(3):769-79.

Watson ME, Lacey LA, McSorley DJ, Kong NS, Northcutt AR, Mangel AW. Patient satisfaction with alosetron for the treatment of irritable bowel syndrome (IBS). Poster presented at the Digestive Disease Week and the 101st Annual Meeting of the American Gastroenterological Association; May 2000. [abstract] Gastroenterology. 2000 Apr; 118((4) Part 1):A219.

Northcutt AR, Camilleri M, Mayer EA, Dossman DA, Dukes GE, Ehsanullah RSB, McSorley DJ. Alosetron, a 5-HT3-receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. Gastroenterology. 1998;114:A812.

Vakil N, McSorley DJ. The incremental cost and utility of cultures for helicobacter pylori. Gastroenterology. 1997;112(4):A319.

Perschy TB, McSorley DJ. Ranitidine bismuth citrate in combination with clarithromycin is effective against h. pylori strains with susceptible or intermediate clarithromycin sensitivity. Gastroenterology. 1997;112(4):A257.

Peterson WL, Sontag SJ, Ciociola AA, Sykes DL, McSorley DJ, Webb DD, the H. pylori Ulcer Group. Ranitidine bismuth citrate plus clarithromycin is effective in the eradication of helicobacter pylori and prevention of duodenal ulcer relapse. Poster presented at the Digestive Disease Week and the 95th Annual Meeting of the American Gastroenterological Association; May 1995. [abstract] Gastroenterology. 1995 Apr; 108(4 (Suppl 1)):A190. doi: 10.1016/0016-5085(95)23422-5

Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of chronic oral dosing of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory activity. Gastroenterology. 1992;102(4):A50.

Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of ascending oral doses of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory properties. Gastroenterology. 1992;102(4):A51.